Lightpoint Medical and Telix Pharmaceuticals Form Strategic Partnership to Enhance Prostate Cancer Detection

Lightpoint Medical, a leading medical device company that develops miniaturized imaging and sensing tools for minimally-invasive and robot-assisted surgery, recently announced a strategic collaboration with Telix Pharmaceuticals Limited, to explore how the the two companies’ technologies can be used for real-time intra-operative cancer detection.

Lightpoint is the maker of SENSEI®, a miniaturized surgical gamma probe utilized for minimally-invasive and robot-assisted cancer surgery. The device, which is approved for sale in the US, EU, UK, and Australia, can be used in conjunction with molecularly-targeted imaging agents to help direct cancer detection during surgery and guide surgeons in the removal of malignancies.

As part of this strategic alliance, Lightpoint and Telix will assess the use of SENSEI® with Telix’s investigational prostate cancer single photon emission computed tomography(SPECT) imaging agent TLX599-CDx (99mTc-HYNIC-iPSMA) for the detection of cancerous pelvic lymph nodes. TLX599-CDx is an investigational product intended to facilitate patient access to advanced prostate cancer imaging in countries where SPECT imaging is predominant.

“This strategic partnership agreement with Telix marks an important milestone for Lightpoint Medical. The combination of our miniaturized surgical gamma probe, SENSEI®, alongside Telix’s ground-breaking imaging agents is intended to create an extremely precise technique to help surgeons detect cancer that might not otherwise be found during surgery, or conversely, confirm the absence of disease to help surgeons retain healthy, functional tissue. The collaboration between our two companies has the potential to transform surgical outcomes for patients across a range of major cancer types, starting with prostate cancer,” remarked Lightpoint CEO Graeme Smith via a press release about the announcement.

Telix CEO, Dr. Christian Behrenbruch added: “Bringing molecular imaging into the operating theatre is a key part of our portfolio strategy for urologic oncology, and the combination of Telix and Lightpoint technologies has the potential to transform treatment options for patients with cancer. This collaboration helps to reinforce Telix’s position as a leader in developing advanced surgical technologies using highly targeted imaging techniques.”